George Peter Canellos

George Peter Canellos's AcademicInfluence.com Rankings

Law

#1984

World Rank

#2468

Historical Rank

Common Law

#61

World Rank

#68

Historical Rank

law Degrees

Download Badge

George Peter Canellos's Degrees

PhD Biomedical Sciences Stanford University

Why Is George Peter Canellos Influential?

(Suggest an Edit or Addition)

(See a Problem?)

George Peter Canellos's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A predictive model for aggressive non-Hodgkin's lymphoma. (1993) (4400)
Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. (1989) (1526)
Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. (1992) (1060)
Dose: a critical factor in cancer chemotherapy. (1980) (831)
Meta‐analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults (1993) (614)
ADVANCED DIFFUSE HISTIOCYTIC LYMPHOMA, A POTENTIALLY CURABLE DISEASE RESULTS WITH COMBINATION CHEMOTHERAPY (1975) (476)
Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. (2003) (461)
Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. (2002) (405)
Cancer of the breast: the past decade (first of two parts). (1980) (403)
Combination versus single agent chemotherapy: A review of the basis for selection of drug treatment of cancer (1975) (377)
Burnout syndrome in the practice of oncology: results of a random survey of 1,000 oncologists. (1991) (376)
Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). (1983) (342)
Nonlymphomatous malignant tumors complicating Hodgkin's disease. Possible association with intensive therapy. (1972) (334)
Chronic granulocytic leukemia. (1976) (328)
SECOND MALIGNANCIES COMPLICATING HODGKIN'S DISEASE IN REMISSION (1975) (328)
Cancer of the breast: the past decade (second of two parts). (1980) (298)
Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis. (1987) (285)
Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. (1986) (274)
L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease. (1969) (255)
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. (2007) (250)
Neonatal megaloblastic anemia due to inherited transcobalamin II deficiency in two siblings. (1971) (239)
Residual mass in lymphoma may not be residual disease. (1988) (232)
Multimodality therapy for malignant mesothelioma based on a study of natural history. (1980) (209)
Differentiation patterns in the blastic phase of chronic myeloid leukemia. (1983) (196)
Lymphomas of the breast (2002) (193)
Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. (2009) (189)
Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: long-term analysis of risk factors and outcome. (1996) (189)
Microangiopathic Hemolytic Anemia and Cancer: A Review (1979) (188)
Sequential nonsurgical and surgical staging of non-Hodgkin's lymphoma. (1976) (176)
Gallium-67 imaging: a predictor of residual tumor viability and clinical outcome in patients with diffuse large-cell lymphoma. (1990) (174)
Clinical implications of cytogenetic variants in chronic myelocytic leukemia (CML). (1968) (173)
Combination chemotherapy for metastatic breast carcinoma. Prospective comparison of multiple drug therapy with L‐phenylalanine mustard (1976) (171)
A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype (2012) (169)
Stage IA and IIA supradiaphragmatic Hodgkin's disease: prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation. (1988) (166)
Potential for prolonged disease-free survival following combination chemotherapy of non-Hodgkin's lymphoma. (1974) (162)
Primary lymphomas of the central nervous system: patterns of failure and factors that influence survival. (1985) (159)
High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity. (1980) (157)
Hematologic and cytogenetic remission of blastic transformation in chronic granulocytic leukemia. (1971) (157)
Hodgkin disease survivors at increased risk for problems in psychosocial adaptation (1992) (154)
l-asparaginase resistance in human leukemia--asparagine synthetase. (1969) (149)
The significance of the residual mediastinal mass in treated Hodgkin's disease. (1985) (142)
Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease. (1995) (139)
ANTI-B1 MONOCLONAL ANTIBODY AND COMPLEMENT TREATMENT IN AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR RELAPSED B-CELL NON-HODGKIN'S LYMPHOMA (1984) (139)
Successful treatment of recurrent primary central nervous system lymphoma with high‐dose methotrexate (1980) (135)
Long-term follow-up of Hodgkin's disease trial. (2002) (131)
Combination chemotherapy for advanced breast cancer: response and effect on survival. (1976) (130)
The m-BACOD combination chemotherapy regimen in large-cell lymphoma: analysis of the completed trial and comparison with the M-BACOD regimen. (1990) (130)
Risk of new cancers in patients with Hodgkin's disease (1977) (130)
Large-cell and immunoblastic lymphoma of the mediastinum: prognostic features and treatment outcome in 57 patients. (1993) (130)
Blast crisis of chronic granulocytic leukemia. Morphologic variants and therapeutic implications. (1977) (128)
Treatment of Hodgkin lymphoma: a 50-year perspective. (2014) (127)
A decade of combination chemotherapy of advanced Hodgkin's disease (1972) (127)
T-cell surface antigens in a patient with blast crisis of chronic myeloid leukemia (1983) (127)
FDG-PET is Superior to Gallium Scintigraphy in Staging and More Sensitive in the Follow-up of Patients with de novo Hodgkin Lymphoma: A Blinded Comparison (2004) (125)
Burnout: caring for the caregivers. (2000) (124)
Prognostic discrimination among younger patients with chronic granulocytic leukemia: relevance to bone marrow transplantation. (1985) (122)
Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. (2008) (121)
Characteristics of blast crisis in chronic granulocytic leukemia. (1977) (121)
The cellular biology of the Reed-Sternberg cell. (1994) (119)
High-dose methotrexate with folinic acid in the treatment of advanced non-Hodgkin lymphoma including CNS involvement. (1977) (118)
High-dose gallium imaging in lymphoma. (1983) (113)
Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. (2008) (109)
Prognostic factors for positive surgical staging in patients with Hodgkin's disease. (1990) (108)
End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma. (2011) (104)
Cyclical Combination Chemotherapy for Advanced Breast Carcinoma (1974) (102)
Malignant lymphoma II. Prognostic factors and response to treatment of 473 patients at the national cancer institute (1982) (101)
HYPERCALCEMIA IN MALIGNANT LYMPHOMA AND LEUKEMIA (1974) (100)
Maintenance chemotherapy for advanced Hodgkin's disease in remission. (1973) (100)
Treatment of ovarian carcinoma: possibilities for progress. (1972) (100)
Thrombocytosis in chronic granulocytic leukemia: incidence and clinical significance. (1974) (97)
The m-BACOD combination chemotherapy regimen in the treatment of diffuse large cell lymphoma. (1987) (95)
High-dose BCNU with autologous bone marrow rescue for recurrent glioblastoma multiforme. (1981) (95)
A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study. (1993) (93)
Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma (2004) (92)
Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease. (1997) (91)
L-asparaginase toxicity. (1969) (87)
Primary Ki-1 anaplastic large-cell lymphoma in adults: clinical characteristics and therapeutic outcome. (1993) (87)
Evidence for genetic restriction in the suppression of erythropoiesis by a unique subset of T lymphocytes in man. (1983) (87)
Effect of megestrol acetate on quality of life in a dose-response trial in women with advanced breast cancer. The Cancer and Leukemia Group B. (1993) (84)
Improved survival following combined radiation therapy and chemotherapy for unfavorable prognosis stage I-II non-Hodgkin's lymphomas. (1985) (82)
Comparison of psychosocial adaptation of advanced stage Hodgkin's disease and acute leukemia survivors. Cancer and Leukemia Group B. (1998) (80)
Hyperkalaemia, a sequel to chemotherapy of Burkitt's lymphoma. (1973) (80)
The kinetics of 67gallium incorporation into inflammatory lesions: experimental and clinical studies. (1974) (79)
Comparison of psychosocial adaptation and sexual function of survivors of advanced hodgkin disease treated by MOPP, ABVD, or MOPP alternating with ABVD (1992) (75)
A Study of Coronary Heart Disease in Young Men: Characteristics and Metabolic Studies of the Patients and Comparison with Age‐Matched Healthy Men (1966) (75)
Treatment of central nervous system tumors with methotrexate. (1981) (72)
Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: Cancer and leukemia Group B protocol 50206 (2007) (71)
LEUKÆMIA AND LOWER-MOTOR-NEURON DISEASE (1974) (68)
Initial clinical trials with methyl‐ccnu 1‐(2‐chloroethyl)‐3‐(4‐methyl cyclohexyl)‐1‐nitrosourea (meccnu) (1973) (64)
DESTRUCTIVE BONE LESIONS IN CHRONIC GRANULOCYTIC LEUKEMIA (1969) (62)
High-dose thymidine infusions in patients with leukemia and lymphoma. (1980) (62)
Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. (2011) (61)
Stage III Hodgkin's disease: improved survival with combined modality therapy as compared with radiation therapy alone. (1985) (61)
Basophilic Chronic Granulocytic Leukaemia with Hyperhistaminaemia (1977) (59)
Combination chemotherapy for advanced Hodgkin's disease in relapse following extensive radiotherapy (1972) (59)
Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B study. (1996) (59)
Studies on the antitumor activity of gallium nitrate (NSC-15200) and other group IIIa metal salts. (1975) (58)
Chemotherapy of the blastic phase of chronic granulocytic leukemia: hypodiploidy and response to therapy. (1976) (58)
How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen? (2004) (55)
Advanced lymphocytic lymphoma: randomized comparisons of chemotherapy and radiotherapy, alone or in combination. (1977) (55)
Treatment of favorable, limited-stage Hodgkin's lymphoma with chemotherapy without consolidation by radiation therapy. (2010) (55)
Autologous bone-marrow transplantation: host effects of high-dose BCNU. (1983) (55)
Patterns of relapse in large-cell lymphoma patients with bulk disease: implications for the use of adjuvant radiation therapy. (1989) (53)
Serum ferritin concentration in untreated Hodgkin's disease. (1976) (53)
Hematologic engraftment and immune reconstitution posttransplantation with anti-B1 purged autologous bone marrow. (1987) (52)
Duration of therapy in adjuvant chemotherapy trials. (1986) (50)
Non‐Hodgkin's lymphoma: Patterns of relapse from complete remission after combination chemotherapy (1975) (48)
Chemotherapy of advanced ovarian carcinoma: a prospective randomized comparison of phenylalanine mustard and high dose cyclophosphamide. (1974) (46)
Chemotherapy of the non‐Hodgkin's lymphomas (1978) (45)
Interim [18F]fluorodeoxyglucose positron emission tomography imaging in stage I–II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone? (2012) (44)
SECOND MALIGNANCIES COMPLICATING HODGKIN'S DISEASE IN REMISSION (1975) (44)
Etoposide, vinblastine, and doxorubicin: an active regimen for the treatment of Hodgkin's disease in relapse following MOPP. Cancer and Leukemia Group B. (1995) (44)
Hodgkin disease in patients 60 years of age or older. Histologic and clinical features of advanced‐stage disease (1993) (43)
Primary mediastinal large-B-cell lymphoma: radiologic findings at presentation. (1996) (43)
Stage IA-IIB Hodgkin's disease: staging and treatment of patients with large mediastinal adenopathy. (1989) (43)
Combination chemotherapy with adriamycin‐cyclophosphamide for advanced ovarian carcinoma (1980) (43)
The treatment of chronic granulocytic leukaemia. (1977) (42)
Extranodal presentation of non‐Hodgkin's lymphomas in the testis (1976) (41)
Sequential staging in non-Hodgkin's lymphoma. (1977) (41)
Anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation for B-cell non-Hodgkin's lymphoma: phenotypic reconstitution and B-cell function. (1989) (40)
Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901 (2007) (40)
T-cell surface antigens in a patient with blast crisis of chronic myeloid leukemia. (1983) (39)
Sequential nonsurgical and surgical staging of non‐Hodgkin's lymphoma (1978) (38)
Wide‐field radiation therapy with or without chemotherapy for patients with Hodgkin disease in relapse after initial combination chemotherapy (1993) (38)
Chemotherapy in the treatment of Hodgkin's disease. (1983) (38)
Successful treatment of metastatic sarcomas with cyclophosphamide, adriamycin, and DTIC (CAD) (1980) (38)
Is there an effective salvage therapy for advanced Hodgkin's disease? (1991) (37)
Predictive factors for long-term survival in patients with advanced ovarian cancer. (1989) (37)
Lens changes in chronic granulocytic leukemia. Possible relationship to chemotherapy. (1969) (37)
What is the appropriate systemic chemotherapy for lymphocyte-predominant Hodgkin's lymphoma? (2010) (37)
Autologous bone marrow transplantation in the treatment of malignant lymphoma and Hodgkin's disease. (1988) (35)
Increased therapeutic index using moderate dose methotrexate and leucovorin twice weekly vs. weekly high dose methotrexate‐leucovorin in patients with advanced squamous carcinoma of the head and neck: A safe new effective regimen (1981) (35)
Hematologic remission and cytogenetic improvement after treatment of stable‐phase chronic myelogenous leukemia with continuous infusion of low‐dose cytarabine (1993) (35)
Structural and functional effects of adriamycin on cardiac cells in vitro. (1980) (34)
Combination chemotherapy for advanced non-Hodgkin's lymphomas other than diffuse histiocytic or undifferentiated histologies. (1984) (34)
Long-term follow-up of survival in Hodgkin's lymphoma. (2009) (34)
Initial clinical evaluation of N-trifluoroacetyladriamycin-14-valerate (AD-32), an adriamycin analog. (1979) (34)
Splenectomy in the chronic phase of chronic granulocytic leukemia. Effects in 32 patients. (2020) (34)
Chemotherapy (cyclophosphamide, vincristine, and prednisone) versus radiotherapy (total body irradiation) for stage III-IV poorly differentiated lymphocytic lymphoma. (1978) (32)
Therapy of advanced lymphocytic lymphoma a preliminary report of a randomized trial between combination chemotherapy (CVP) and intensive radiotherapy. (1975) (32)
Survival of patients with localized high‐grade soft tissue sarcoma with multimodality therapy: A matched control study (1983) (32)
Dose‐escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma (2001) (32)
Autologous bone marrow transplantation following high-dose chemotherapy with cyclophosphamide, BCNU and VP-16 in small cell carcinoma of the lung and a review of current literature. (1984) (32)
Intensive chemotherapy for Hodgkin's disease: long-term complications. (1973) (31)
A therapeutic trial of maytansine. (1978) (31)
Computed Tomography of the Abdomen and Pelvis in Non‐Hodgkin Lymphoma (1983) (30)
Persistent symptoms among survivors of Hodgkin's disease: an explanatory model based on classical conditioning. (2001) (29)
Chemotherapy alone for early Hodgkin's lymphoma: an emerging option. (2005) (29)
Reduction of fatal complications from combined modality therapy in Hodgkin's disease. (1985) (28)
Prolonged disease-free survival in advanced breast cancer treated with "super-CMF" adriamycin: an alternating regimen employing high-dose methotrexate with citrovorum factor rescue. (1981) (28)
Prognostic factors and treatment outcome in patients with primary progressive and relapsed Hodgkin's disease. (2002) (27)
Stage IA-IIB Hodgkin's disease: management and outcome of extensive thoracic involvement. (1997) (26)
Long-term complications of MOPP chemotherapy in patients with Hodgkin's disease. (1982) (26)
Primary systemic treatment of advanced Hodgkin's disease with EVA (etoposide, vinblastine, doxorubicin): 10-year follow-up. (2003) (26)
Clinical Oncology: Onward and Upward (2008) (26)
The management of early breast cancer (1982) (25)
Mantle irradiation alone for selected patients with laparotomy-staged IA to IIA Hodgkin's disease: preliminary results of a prospective trial. (1995) (25)
The second chance for advanced Hodgkin's disease. (1992) (24)
Selection bias in trials of transplantation for metastatic breast cancer: have we picked the apple before it was ripe? (1997) (23)
Treatment of relapsed Hodgkin's disease: strategies and prognostic factors. (1998) (22)
The dose dilemma. (1988) (22)
Methotrexate as a single agent and in combination chemotherapy for the treatment of non-Hodgkin's lymphoma of unfavorable histology. (1981) (22)
Can MOPP be replaced in the treatment of advanced Hodgkin's disease? (1990) (21)
Biocmical and pharmacologic effects of L-asparaginase in man. (1970) (21)
Effect of splenectomy on tolerance to combination chemotherapy in patients with lymphoma. (1976) (21)
Hypoalbuminemic and hypocholesterolemic effect of L-asparaginase (NSC-109,229) treatment in man--a preliminary report. (1969) (21)
Clinical characteristics of the blast phase of chronic granulocytic leukemia. (1990) (20)
Myelosuppression and "conventional" chemotherapy: what price, what benefit? (1993) (20)
CHOP may have been part of the beginning but certainly not the end: issues in risk-related therapy of large-cell lymphoma. (1997) (20)
Chemotherapy of advanced non-Hodgkin's lymphoma. (1979) (20)
Chlorambucil, vinblastine, procarbazine, and prednisone. An effective but less toxic regimen than MOPP for advanced‐stage Hodgkin's disease (1989) (19)
Hypercalcemia in chronic granulocytic leukemia (1971) (19)
Splenectomy for thrombocytopenia in chronic granulocytic leukemia (1972) (19)
Quality of life in patients with limited small-cell carcinoma of the lung receiving chemotherapy with or without radiation therapy, for cancer and leukemia group B. (1997) (19)
Phase II trial of topotecan in advanced breast cancer: a Cancer and Leukemia Group B study. (1999) (18)
Evidence for granulocytic incorporation of 67gallium in chronic granulocytic leukemia. (1974) (18)
Bone marrow transplantation as salvage therapy in advanced Hodgkin's disease: allogeneic or autologous. (1985) (18)
High-dose methotrexate with leucovorin rescue in ovarian cancer: a phase II study. (1979) (17)
Small non‐cleaved cell lymphoma in adults (1991) (16)
Phase I trial of N-(Phosphonacetyl)-L-aspartic acid (PALA). (1980) (16)
Surgical therapy of localized abdominal non-Hodgkin's lymphomas. (1988) (16)
Autologous peripheral stem cell transplantation of the blastic phase of chronic myeloid leukemia following sequential high‐dose cytosine arabinoside and melphalan (1994) (15)
Treatment of low‐grade and intermediate‐grade lymphoma with intensive combination chemotherapy results in long‐term, disease‐free survival (1990) (15)
Effect of chemotherapy and irradiation on interactions between stromal and hemopoietic cells in vitro. (1982) (15)
Asparagine biosynthesis in human KB tumor cells: inhibitor studies with asparagine and glutamine antagonists. (1970) (15)
Mediastinal Large Cell Lymphoma: Prognostic Significance ofCT Findings at Presentation and after Treatment (1998) (14)
Letter: Leukaemia and lower-motor-neuron disease. (1974) (14)
Combination chemotherapy and survival in advanced Hodgkin's disease. (1973) (14)
Hypoglycorrhachia in meningeal carcinomatosis (1966) (14)
Results of combination chemotherapy of non-Hodgkin's lymphoma. (1975) (14)
High-dose therapy: here to stay or just visiting? (1994) (13)
Therapy-related leukemia: a necessary complication of successful systemic chemotherapy? (1984) (13)
Lymphoma: present and future challenges. (2004) (13)
Treatment of the blastic transformation of chronic granulocytic leukemia using high dose BCNU chemotherapy and cryopreserved autologous peripheral blood stem cells (1985) (12)
The case for high-dose chemotherapy: is it chemotherapy's last gamble? (1987) (12)
Splenic enlargement and hyperfunction as indications for splenectomy in chronic leukemia. (1987) (12)
Chronic granulocytic leukemia: the heterogeneity of stem cell differentiation within a single disease entity. (1985) (12)
New treatments for advanced Hodgkin's disease: an uphill fight beginning close to the top. (2002) (12)
Preliminary Results of trials of chemotherapy in advanced ovarian carcinoma. (1975) (12)
Monoclonal antibodies: their use in bone marrow transplantation. (1987) (12)
Is ABVD the standard regimen for Hodgkin's disease based on randomized CALGB comparison of MOPP, ABVD and MOPP alternating with ABVD? (1996) (11)
High-dose intermittent intravenous infusion of procarbazine (NSC-77213). (1973) (11)
Current strategies for early Hodgkin's disease. (1996) (11)
High dose intravenous bleomycin in the treatment of advanced lymphomas. (1975) (11)
Phase I and preliminary phase II study of neocarzinostatin. (1978) (11)
Doxorubicin, Vinblastine and Gemcitabine (AVG), a Novel Regimen Excluding Bleomycin for the Treatment of Early Stage Hodgkin Lymphoma (HL): Results of CALGB 50203. (2007) (11)
Aberrant p53 Staining Does Not Predict Cisplatin Resistance in Locally Advanced Non-Small Cell Lung Cancer (2002) (11)
Mediastinal adenopathy in granulocytic leukemia. (1974) (11)
Clinical value of ultrasonography for the management of non-Hodgkin lymphoma patients as compared with abdominal computed tomography. (1983) (11)
Myocardial infarction in one of a pair of twenty-seven year old identical male twins. (1963) (11)
Late recurrence of testicular tumor. (1972) (10)
Treatment of advanced Hodgkin’s disease (1999) (10)
RECENTLY RECOGNIZED COMPLICATIONS OF CANCER CHEMOTHERAPY (1974) (10)
Phase I trial of mitoxantrone by 24-hour continuous infusion. (1983) (10)
Brentuximab vedotin and panobinostat: new drugs for Hodgkin's lymphoma--can they make one of medical oncology's chemotherapy success stories more successful? (2012) (10)
Hematology in 2010: New therapies and standard of care in oncology (2011) (10)
CALGB 59901: Results of a Phase II Study of 506U78 in CTCL and PTCL. (2004) (10)
Brentuximab Vedotin for Stage III or IV Hodgkin’s Lymphoma. (2018) (9)
Primary treatment of Hodgkin's disease. (2002) (9)
Role of 99mTc methylene diphosphonate bone imaging in the management of lymphoma. (1985) (9)
Improved survival in patients with limited stage IIIA Hodgkin's disease treated with combined radiation therapy and chemotherapy. (1994) (9)
Phase I trial of bruceantin. (1979) (9)
Treatment of the Elastic Phase of Chronic Myelogenous Leukemia with High‐Dose Cytosine Arabinoside (1988) (9)
Pharmacologic studies in man with crystallized L-asparaginase (NSC-109229). (1972) (8)
Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes. (1993) (8)
The treatment of locally advanced breast cancer. (1984) (8)
Relapsed and refractory Hodgkin's lymphoma: new avenues? (2007) (8)
Relapse with Nodular Lymphoma Following Combination Chemotherapy for Diffuse Non‐Hodgkin's Lymphoma (1986) (8)
Early Interim FDG-PET Scan Predicts Outcome in Non-Bulky Limited Stage Hodgkin Lymphoma, but may Not Guide Use of Consolidative Radiotherapy. (2008) (7)
Recombinant interferon-α2b added to oral cyclophosphamide either as induction or maintenance in treatment-naive follicular lymphoma: final analysis of CALGB 8691 (2009) (7)
Phase II study of dose-adjusted EPOCH-R in untreated de novo CD20+ diffuse large B-cell lymphoma (DLBCL)-CALGB 50103 (2005) (7)
Effect of L-asparaginase on mouse bone marrow, assayed by in vitro culture. (1970) (7)
cis-Diamminedichloroplatinum(II) therapy for advanced ovarian cancer. (1980) (7)
Chapter 12 – THE TOXICITY OF HIGH-DOSE BCNU WITH AUTOLOGOUS MARROW SUPPORT1 (1981) (6)
High‐dose cytosine arabinoside in relapsed and refractory non‐Hodgkin's lymphoma. Limited role as a single agent (1989) (6)
Immuno-Chemotherapy (IC) and Autologous Stem Cell Transplant (ASCT) for Untreated Patients (pts) with Mantle Cell Lymphoma (MCL): CALGB 59909. (2006) (5)
Treatment of the non-Hodgkin's lymphomas. (1978) (5)
A Chemotherapeutic Approach to CNS Lymphoma and Leukaemia by the Systemic Administration of High Doses of Antimetabolites (1979) (5)
The effect of treatment with cytotoxic agents on mouse spleen dihydrofolate reductase activity. (1967) (5)
Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: Results of CALGB 59906 (2006) (5)
Interim FDG PET Imaging in CALGB 50203 Trial of Stage I/II Non-Bulky Hodgkin Lymphoma: Would Using Combined PET and CT Criteria Better Predict Response Than Each Test Alone?, (2011) (5)
Current therapeutic strategies in Hodgkin's disease. (1992) (5)
Clinical research saves money: reflections on high-dose therapy of breast cancer. (1999) (4)
A new addition to the Journal of Clinical Oncology: the art of oncology--when the tumor is not the target. (2000) (4)
Therapy of the Blastic Phase of Chronic Granulocytic Leukemia (1970) (4)
Combination Chemotherapy of Solid Tumors: An American-Italian Collaboration: A Celebration of the work of Gianni Bonadonna (2016) (4)
L-asparaginase treatment of acute myeloblastic leukemia. (1970) (4)
Treatment of refractory splenomegaly in myeloproliferative disease by splenic artery infusion. (1979) (4)
Systemic therapy of breast cancer (1988) (4)
Proceedings: Malignant lymphoma: treatment with combination chemotherapy. (1972) (4)
Who should pay for clinical research? (1990) (3)
Hematology in 2010: New therapies and standard of care in oncology (2011) (3)
Reconstitution or resurrection of normal stem cells in chronic granulocytic leukemia. (1979) (3)
Can Low-Risk, Early-Stage Patients with Hodgkin Lymphoma Be Spared Radiotherapy? (2011) (3)
Chemotherapy Alone for Localized Non-Bulky Hodgkin Lymphoma (2008) (3)
Asparaginase and leukaemia. (1969) (3)
What constitutes "improved prognosis"? (2008) (3)
Transplantation with anti-B1 monoclonal antibody and complement treated autologous bone marrow for relapsed B-cell non-Hodgkin’s lymphoma (1985) (3)
High dose CHOP: A phase II study of initial treatment in aggressive non-Hodgkin lymphoma. Cancer and Leukemia Group B 9351 (2007) (3)
Is chemotherapy alone for early Hodgkin lymphoma an emerging therapeutic option? (2009) (3)
Clinical trials in North America (2005) (3)
Critical review of the role of hemopoietic growth factors in dose intensification and outcome in the treatment of non-Hodgkin's lymphoma. (1994) (2)
Methotrexate-leucovorin factor rescue regimens in diffuse large cell lymphoma. (1987) (2)
Randomized comparison of chemotherapy (CVP) and radiotherapy (TBI) in stage III–IV poorly differentiated lymphocytic lymphoma (1978) (2)
L-asparaginase and Burkitt's lymphoma. (1969) (2)
Book ReviewAnticancer Drugs (1980) (2)
Studies of resistance to L-asparaginase in human leukemia. (1970) (2)
Phenacetin induced heinz body formation in rats with intestinal blind loops abstract (1967) (2)
Reply to M. Ozsahin et al (2010) (2)
Recent issues in chemotherapy for Hodgkin's disease. (1989) (2)
Eradication of Minimal Residual Disease during Treatment of Mantle Cell Lymphoma: CALGB 59909. (2004) (2)
Hodgkin's Disease (1984) (2)
Hormonal agents and treatment of cancer. (1986) (2)
Where does hematology end and oncology begin? Questions of professional boundaries and medical authority. (2006) (2)
54: Inclusion of Sirolimus in the GVHD Prophylaxis Regimen is Associated with Improved Survival in Patients with Lymphoma Undergoing Allogeneic Transplantation (2008) (1)
Clinical Significance of the Philadelphia Chromosome in Chronic Granulocytic Leukemia. (1968) (1)
Chapter 15 – BACOP AND RELATED STUDIES IN NON-HODGKIN'S LYMPHOMA (1985) (1)
Kinetics of $sup 67$Ga incorporation into inflammatory lesions: experimental and clinical studies (1974) (1)
Evaluation of adriamycin (ADR) cardiotoxicity (CT) using an in vitro rat heart cell system (1979) (1)
The Cancer and Leukemia Group B Lymphoma Committee (2006) (1)
Mechanisms of l-asparaginase resistance, asparagine synthetase (asase) in animal and human neoplasms. Abstr. (1969) (1)
Stat Bite Oncologists Experience Burnout (1991) (1)
Lymphoma Update: 1997 (1997) (1)
An in vitro assay for the effect of chemotherapy on bone marrow stromal cell support of donor hemopoietic stem cell proliferation (1980) (1)
The Chronic Leukemias (1989) (1)
Intense Immunochemotherapy (IC) and Autologous Stem Cell Transplant (ASCT) for Untreated Patients (pts) with Mantle Cell Lymphoma (MCL): CALGB 59909. A Preliminary Report. (2004) (1)
ASCO 30 years later: the state of the Society. (1994) (1)
Occasional notes. The management of early breast cancer. (1982) (1)
New biologic and therapeutic insights in Hodgkin's lymphoma (2009) (0)
E05 New issues in the management of localized Hodgkin's lymphoma (2007) (0)
Pharmacy Focus (1990) (0)
Modifications of techniques for storage and reinfusion of chronic granulocytic leukemia (CGL) peripheral blood stem cells (BSC) (1981) (0)
Letter: Combination chemotherapy for breast cancer. (1975) (0)
Treatment for favorable localized Hodgkin lymphoma: the final answer is awaited. (2012) (0)
Professor timothy McElwain : medical oncology loses a british leader (1991) (0)
Renal cell cancer (2011) (0)
Sequential Topoisomerase I (Topo I) and Topoisomerase II (Topo II) Inhibitors in Relapsed/Refractory Aggressive NHL: Results of CALGN 59906, a Phase II Study of Doxorubicin and Topotecan. (2004) (0)
Advanced DLBCL: as systemic therapy improves, the need for RT diminishes. (2014) (0)
Proceedings: The chronic leukemias: current therapeutic concepts. (1972) (0)
Comparison of the psychosocial adaptation of survivors of Hodgkin's disease and leukemia (1991) (0)
In vitro quantitation of chemotherapy effects on bone marrow stromal cell support of engrafted hematopoietic stem cells. Abstr. (1980) (0)
Is CHOP the standard of therapy for poor-prognosis large-cell lymphoma? (1997) (0)
Metabolic Studies of the Patients and Comparison with Age-Matched A Study of Coronary Heart Disease in Young Men: Characteristics and (2005) (0)
Evidence for granulocytic incorporation of $sup 67$Ga in chronic granulocytic leukemia (1974) (0)
Second malignancies and cancer therapy (1985) (0)
Leukemia (CML) Clinical Implications of Cytogenetic Variants in Chronic Myelocytic (2011) (0)
Validation of the International Harmonization Project (IHP) Guidelines in Early Stage Hodgkin Lymphoma (HL) Treated with Adriamycin, Vinblastine and Gemcitabine (AVG) (CALGB 50203): Early Results. (2008) (0)
The role of alkylating agents in acute and chronic leukemia. (1989) (0)
Treatment of the leukemias. (1978) (0)
Book ReviewCancer Chemotherapy 1982 (1983) (0)
Joseph R. Bertino, Scientist and Clinical Oncologist. (2022) (0)
Diagnosis and treatment of Hodgkin's disease. (1978) (0)
Book ReviewCancer and Chemotherapy, Volume 1: Introduction to neoplasia and antineoplastic chemotherapy (1981) (0)
Contents, Vol. 62, 1994 (1994) (0)
Reply to G. Basaran et al (2010) (0)
Prognostic factors for patients with hodgkin disease in first relapse (0)
Randomized C omparison o f A BVD a nd M OPP/ABV H ybrid f or the T reatment o f A dvanced H odgkin's D isease: R eport o f a n Intergroup T rial (2003) (0)
Oncologic emergencies. (1978) (0)
Role of Haemopoietic Growth Factors in Lymphoma Therapy (1995) (0)
Experimental and clinical studies of gallium. Abstr. (1972) (0)
Editorial: Combination chemotherapy for breast cancer. (1975) (0)
Report o f a n I nternational W orkshop t o S tandardize Response C riteria f or N on-Hodgkin's L ymphomas (1999) (0)
splenic artery infusion Treatment of refractory splenomegaly in myeloproliferative disease by (2012) (0)
Historical prospect for the concept of primary extranodal lymphoma (2008) (0)
Book Review The Non-Hodgkin's Lymphomas Edited by Ian T. Magrath. 430 pp., illustrated. Baltimore, Williams and Wilkins, 1990. $72.50. (1990) (0)
Reply to A. Horwich et al (2010) (0)
Prognostic factors in large-cell lymphoma. (2003) (0)
Book ReviewCancer Treatment (1980) (0)
Introduction to a special series of unique entities within the spectrum of large-cell lymphoma. (2006) (0)
Treatment of chronic granulocytic leukemia in blastic crisis. (1989) (0)
Asparaginase: Early Clinical and Toxicology Studies (1970) (0)
Has the MOPP era ended? (1991) (0)
Surface Antigens in a Patient With Blast Crisis of Chronic Myeloid Leukemia (2005) (0)
A History of the Chronic Leukemias (2018) (0)
Experimental approaches in the treatment of lymphoma. (1987) (0)
Non-Myeloablative Allogeneic Transplantation for Hodgkin’s and Non-Hodgkin’s Lymphoma: Evidence for a Graft-Versus-Lymphoma Effect and Relevance of Chimerism. (2007) (0)
The effect of androgenic steroids on granulopoiesis. Abstr. (1971) (0)
Chemotherapy of Non-Hodgkin's Lymphoma Potential for Prolonged Disease-free Survival Following Combination (2011) (0)
Management of Isolated Metastases and Advanced Renal Carcinoma (1983) (0)
Reply to J. Mehta (2009) (0)
Will doxorubicin-containing regimens replace MOPP and its variants? (1991) (0)
Wiley series on cancer investigation and management (1984) (0)
My Last Post (2001) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With George Peter Canellos?

George Peter Canellos is affiliated with the following schools: